


Empagliflozin slows kidney disease progression and cardiovascular death in at-risk CKD patients


The EMPA-KIDNEY collaboration trial

Anita Purdy
July 2024
Seattle, WA



EMPA-KIDNEY trial

BACKGROUND




Application of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney disease

RESEARCH TRIAL



Characteristics of participants and trial procedures


OUTCOMES



Primary outcomes and results of using empagliflozin for patients with chronic kidney disease

EMPA-KIDNEY trial

BACKGROUND




Application of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney disease

RESEARCH TRIAL



Characteristics of participants and trial procedures

OUTCOMES



Primary outcomes and results of using empagliflozin for chronic kidney disease patients

The intersection of sodium glucose cotransporter 2 inhibitors (SGLT2i)



Figure adapted from Chan JCH. *Medicina*. 2023;59(2):10.

The intersection of sodium glucose cotransporter 2 inhibitors (SGLT2i)




Figure adapted from Chan JCH. *Medicina*. 2023;59(2):10.

The intersection of sodium glucose cotransporter 2 inhibitors (SGLT2i)





Figure adapted from Chan JCH. *Medicina*. 2023;59(2):10.

EMPA-KIDNEY trial

BACKGROUND




Application of sodium-glucose cotransporter-2 inhibitors (SLGT2i) in kidney disease

RESEARCH TRIAL



Characteristics of participants and trial procedures

OUTCOMES



Primary outcomes and results of using empagliflozin for chronic kidney disease patients

Randomized, double-blind, multicenter trial (Feb 2019 – Apr 2021)




eGFR	20-44 ml per minute per 1.73 m ²	45-89 ml per minute per 1.73 m ²
Urinary ACR	Any ACR	ACR ≥ 200 mg/g RAS-inhibitor

Characteristics of participants at randomization

6,609 Study Subjects	
Gender	33% female
Mean age	63.8 years old
No prior CVD	74% no CVD
No prior diabetes	54% no diabetes
Urinary ACR > 300 mg/g	52% urinary ACR > 300 mg/g
RAS-inhibitor	86% RAS-inhibitor use

EMPA-KIDNEY trial

BACKGROUND




Application of sodium-glucose cotransporter-2 inhibitors (SLGT2i) in kidney disease

RESEARCH TRIAL



Characteristics of participants and trial procedures

OUTCOMES




Primary outcomes and results of using empagliflozin for chronic kidney disease patients


PRIMARY CARDIO-RENAL OUTCOME EVENTS

(HR, 0.72; 95% CI, 0.64 to 0.82; $P < .001$)

Percent of kidney disease progression or death from cardiovascular complications according to number of years on treatment*

*Empagliflozin represented **42 fewer primary outcome events per 1000 patients treated for 2 years**





EMPAGLIFLOZIN

Effectively reduces the combined outcome of kidney disease progression or cardiovascular death in patients at risk for CKD progression, regardless of diabetic status.

Thank You